SCHEMBL20239248

SCHEMBL20239248

CNS(=O)(=O)Cc1ccc(Oc2cc(Cl)nc(C(F)(F)F)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 1/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 3/20 0.37
ATM Q13315 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PGR P06401 1/20 0.35
POLB P06746 1/20 0.35
BLM P54132 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
LMNA P02545 2/20 0.35
ESR1 P03372 3/20 0.34
DGAT2 Q96PD7 1/20 0.34
CHRM5 P08912 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16738667 0.83 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1
SCHEMBL20239169 0.82 DGAT2 (0.54) SMN1; SMN2ALDH1A1KDM4EATMCYP1A2
SCHEMBL20239279 0.81 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1
SCHEMBL20239252 0.81 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1
SCHEMBL20239334 0.80 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1
SCHEMBL20239163 0.79 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1
SCHEMBL18249762 0.79 GRM5 (0.44) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1
SCHEMBL20239295 0.78 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1RAB9AMEN1KMT2A
SCHEMBL20239322 0.78 DGAT2 (0.44) SMN1; SMN2RAB9AKDM4EATMPOLB
SCHEMBL20252426 0.77 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1RAB9AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT SMN1; SMN2 4828/4885ALDH1A1 1430/4885RAB9A 1170/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT SMN1; SMN2 4835/4885ALDH1A1 1189/4885RAB9A 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.